Tyroserleutide + Mitomycin + Fluorouracil

This is a combination regimen of three agents: tyroserleutide, mitomycin, and fluorouracil. Fluorouracil (also known as 5-FU) is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, thereby blocking DNA synthesis and leading to cell death. It can also be incorporated into RNA, disrupting RNA processing and protein synthesis[3][6]. Mitomycin (commonly used as mitomycin C) is an antitumor antibiotic that acts as an alkylating agent after metabolic activation, cross-linking DNA and inhibiting DNA synthesis. Tyroserleutide's mechanism of action is less well characterized in the public domain; it has been described in some research contexts but does not have established clinical use or regulatory approval like the other two drugs. The combination of mitomycin and fluorouracil is approved for use with radiotherapy (chemoradiation) for cancers such as anal cancer, bladder cancer, and vulvar cancer[1][2][5][7]. This regimen exploits the synergistic cytotoxic effects on rapidly dividing tumor cells.

Other names

5-fluorouracil5FUmitomycin C